Clinical Trials

Savara Inc., a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare…
Read More...

Valeant Pharmaceuticals International, Inc.'s wholly owned subsidiary, Bausch + Lomb, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA)…
Read More...

Results from the phase 3 REPROVE study assessing Pfizer's fixed-dose antibacterial combo Zavicefta (ceftazidime-avibactam) in patients with hospital-acquired pneumonia (HAP)…
Read More...

Science 37 has raised $29m in Series C funding, led by Glynn Capital Management with participation from GV, to bring clinical trials directly into patients’ homes. The round included…
Read More...

Sutro Biopharma Inc named Crestovo CEO and COO Joseph M. Lobacki to its board of directors. Mr. Lobacki previously served as chief commercial officer of Medivation. He also served…
Read More...

CryoLife announced that the results from the On-X aortic heart valve PROACT study will be presented in a late-breaking session at the AATS (American Association for Thoracic Surgery)…
Read More...

Recipharm, the contract development and manufacturing organisation (CDMO), has opened a newly built GMP suite for clinical trial material (CTM) manufacture at its facility in Research…
Read More...

Novartis announced an expanded commercialization agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine. This agreement builds on a 2015…
Read More...

Ge announced that United BioPharma Inc. (UBP) has selected GE Healthcare’s FlexFactory manufacturing platform for its new facility in Hsinchu Industrial Park, Taiwan focusing on…
Read More...

The Feinstein Institute for Medical Research, and TheraSource LLC, a Long Island-based biotech company, announce today that they have received a Phase I Small Business Technology…
Read More...

NGM Bio’s NGM282 has met the primary and key secondary endpoints in a Phase 2 trial in nonalcoholic steatohepatitis (NASH) patients. NGM282, which is a non-tumorigenic, engineered…
Read More...

Tiziana Life Sciences plc, a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, today announces the approval in Israel of a phase II…
Read More...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CTL019, an investigational chimeric antigen receptor T cell (CAR-T)…
Read More...

Agenus Inc. announced that the first patient has been dosed in a Phase 1/2 clinical trial of its anti-PD-1 antibody, AGEN2034. The open-label, dose-escalation portion of the trial is…
Read More...

uniQure N.V. announced that it will not pursue the renewal of the Glybera (alipogene tiparvovec) marketing authorization in Europe when it is scheduled to expire on October 25, 2017.…
Read More...

ReForm Biologics, a pharmaceutical technology company that develops proprietary excipients to improve biologic formulations, announced that the Company’s Board of Directors has…
Read More...

A certified CDISC provider and leader in pharmacometrics, Certara has developed a new solution which will enable sponsors to achieve new compliance requirements effortlessly
Read More...

Veeva Systems announced Veeva Vault SiteExchange, a cloud application that allows life sciences companies, CROs, and sites to easily access and exchange information during clinical…
Read More...

Regen BioPharma has identified three new series of compounds that activate NR2F6. These compounds are small molecules and were identified using Regen's patented screening methodology…
Read More...